HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines

Tissue Antigens

Volumn 51, Issue 6, 1998, Pages 623-636

  Koopman, L A ^a   Mulder, A ^a   Corver, W E ^a   Anholts, J D H ^a   Giphart, M J ^a   Claas, F H J ^a   Fleuren, G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Downregulation; HLA class I expression; Mechanisms; Monoclonal antibodies

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CONTROLLED STUDY; DNA DETERMINATION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE INDUCTION; GENETIC HETEROGENEITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY LOSS; HLA SYSTEM; HLA TYPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; UTERINE CERVIX CARCINOMA;

EID: 0031801838     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb03005.x     Document Type: Article

References (51)

1. Stern PL. Immunity to human papillomavirus-associated cervical neoplasia. Adv Cancer Res 1996: 69: 175-211.
2. Garrido F, Cabrera T, Concha A, Glew SS, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993: 14: 491-9.
3. Hilders CGJM, Houbiers JGA, Krul EJT, Fleuren GJ. The expression of histocompatibility-relat d leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994: 101: 5-12.
4. Cromme FV, Meijer CJ, Snijders PJ et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 1993: 67: 1372-80.
5. Keating PJ, Cromme FV, Duggan-Keen M et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995: 72: 405-11.
6. Honma S, Tsukada S, Honda S et al. Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int J Cancer 1994: 57: 650-5.
7. Van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996: 62: 33-41.
8. Duggan-Keen MF, Keating PJ, Stevens FRA et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet 1996: 23: 275-84.
9. Hilders CGJM, Morgado Munoz I, Nooyen Y, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995: 57: 366-75.
10. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997: 18: 89-95.
11. Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 1997: 24: 293-312.
12. Cromme FV, Snijders PJ, van den Brule AJ, Kenemans P, Meijer CJ, Walboomers JM. MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 1993: 8: 2969-75.
13. Shin KH, Tannyhill RJ, Liu X, Park NH. Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells. Oncogene 1996: 12: 1089-96.
14. Kisseljov F, Semionova L, Samoylova E et al. Instability of chromosome 6 microsatellite repeats in human cervical tumors carrying papillomavirus sequences. Int J Cancer 1996: 69: 484-7.
15. Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB, Klinger HP. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996: 56: 197-205.
16. Rader JS, Kamarasova T, Huettner PC, Li L, Li Y, Gerhard DS. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene 1996: 13: 2737-41.
17. Hilders CGJM, Ras L, Van Eendenburg JDH, Nooyen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma, Int J Cancer 1994: 57: 805-13.
18. Tieben LM, Ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993: 42: 265-79.
19. Walboomers JMM, Melkert PW, Brule AJCv, Snijders PJF, Meijer CJLM. The polymerase chain reaction for human papillomavirus screening in diagnostic cytopathology of the cervix. In: Herrington CS, McGee JO, ed. Diagnostic molecular pathology. A practical approach. Oxford: Oxford University press 1992: 153-72.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16: 1215.
21. Kersemaekers AF, Hermans J, Fleuren GJ, Vijver Mvd. Loss of heterozygosity for defined regions on chromosomes 3, 11, and 17 in carcinomas of the uterine cervix. Br J Cancer 1998: 77: 192-200.
22. Tonks S, Marsh SG, Bunce et al. HLA Class I DNA typing study. In: Charron D, Fauchet R, ed. Proceedings of the Twelfth International Histocompatibility Workshop. Paris: EDK, 1997: 1: 199-215.
23. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993: 41: 119-34.
24. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation [see comments]. Tissue Antigens 1992: 39: 225-35.
25. Mulder A, Kardol M, Blom J, Jolley WB, Melief CJ, Bruning JW. Characterization of two human monoclonal antibodies reactive with HLA-B12 and HLA-B60, respectively, raised by in vitro secondary immunization of peripheral blood lymphocytes. Hum Immunol 1993: 36: 186-92.
26. Corver WE, Cornelisse CJ, Hermans J, Fleuren GJ. Limited loss of nine tumor-associated surface antigenic determinants after tryptic cell dissociation. Cytometry 1995: 19: 267-72.
27. Maio M, Gulwani B, Morgano A, Ferrone S. Differential modulation by tumor necrosis factors and immune interferon of HLA class II antigens expressed by melanoma cells. Int J Cancer 1989: 44: 554-9.
28. Hanifi Moghaddam P, de Knijf P. Roep BO et al. The genetic structure of IDDM1: two separate regions in the MHC contribute to susceptibility or protection. Diabetes 1998: 47: 259-65.
29. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989: 44: 388-96.
30. Foissac A, Crouau Roy B, Faure S, Thomsen M, Cambon Thomsen A. Microsatellites in the HLA region: an overview. Tissue Antigens 1997: 49: 197-214.
31. Le Bouteiller P. HLA class I chromosomal region, genes, and products: facts and questions. Crit Rev Immunol 1994: 14: 89-129.
32. Mine H, Ishakawa Y, Hojo M et al. An HLA-B null allele (B*1526N) with a stop codon in exon 3 generated by a point mutation. Tissue Antigens 1997: 50: 351-4.
33. Laforet M, Froelich N, Parissiadis A et al. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*01 allele. Tissue Antigens 1997: 50: 347-50.
34. Marincola FM, Shamamian P, Alexander RB et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994: 153: 1225-37.
35. Browning M, Petronzelli F, Bicknell D et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996: 47: 364-71.
36. Torres MJ, Ruiz-Cabello F, Skoudy A et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996: 47: 372-81.
37. Magor KE, Taylor EJ, Shen SY et al. Natural inactivation of a common HLA allele (A*2402) has occurred on at least three separate occasions. J Immunol 1997: 158: 5242-50.
38. Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA Class I antigen expression. Tissue Antigens 1996: 47: 382-90.
39. Lehmann F, Marchand M, Hainaut P et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995: 25: 340-7.
40. Ressing ME, Van Driel WJ, Celis E et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996: 56: 582-8.
41. Evans E, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997: 57: 2943-50.
42. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens. Cell 1987: 14: 9-20.
43. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF. Monoclonal antibodies for analysis of the HLA system. Immunol Rev 1979: 47: 3-61.
44. McMichael AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol 1980: 1: 121-9.
45. Foung SK, Taidi B, Ness D, Grumet FC. A monoclonal antibody against HLA-A11 and A24. Hum Immunol 1986: 15: 316-9.
46. Radka SF, Kostyu DD, Amos DB. A monoclonal antibody directed against the HLA-Bw6 epitope. J Immunol 1982: 128: 2804-6.
47. Brodsky M, Bodmer WF, Parham P. Characterization of a monoclonal anti-beta2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol 1979: 9: 536-45.
48. Berger AE, Davis JE, Cresswell P. Monoclonal antibody to HLA-A3. Hybridoma 1982: 1: 87-90.
49. Haynes BF, Reisner EG, Hemler ME, Strominger JL, Eisenbarth GS. Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group. Hum Immunol 1982: 4: 273-85.
50. Parham P. Monoclonal antibodies against two separate alloantigenic sites of HLA-B40. Immunogenetics 1981: 13: 509-27.
51. Ellis SA, Taylor C, McMichael A. Recognition of HLA-B27 and related antigen by a monoclonal antibody. Hum Immunol 1982: 5: 49-59.